Safety and Efficacy of Botulinum Toxin Type A (BOTOX) to Treat Chronic Migraine in Korea

Trial Profile

Safety and Efficacy of Botulinum Toxin Type A (BOTOX) to Treat Chronic Migraine in Korea

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 07 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 Planned primary completion date changed from 1 May 2015 to 1 Apr 2015 as repoted by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top